BioNexus Gene Lab Corp (BGLC) Stock & Financials
BioNexus Gene Lab Corp (BGLC) is a company.
What to check next
For informational purposes only. Not investment advice. Data may be delayed or inaccurate; verify independently. The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results. Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing.
BioNexus Gene Lab Corp Financial Health ScoreFY2025
Weak financial health; requires careful evaluation
-4 pts YoYThis Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- Altman Z-Score 5.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
BioNexus Gene Lab Corp Recent Events
Source: SEC EDGAR 8-K Filings
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026
About BioNexus Gene Lab Corp
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Profitability Data Under ReviewProfitability metrics are being verified. Some SEC filing data may require additional validation.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
Balance Sheet Data LimitedInsufficient data to assess financial health.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026
BioNexus Gene Lab Corp 7-Year Revenue, Profit & Cash Flow History
Revenue has grown at a 97.0% CAGR over the past 6 years.
Annual Financials
FY2025 - FY2019| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $7.4M(-21.9%) | $9.5M(-2.7%) | $9.8M(-10.6%) | $10.9M(-18.2%) | $13.4M(+17.3%) | $11.4M(+8872.0%) | $126,955 |
| Net Income | $-2,984,607(-86.7%) | $-1,598,342(+39.2%) | $-2,629,043(-638.6%) | $-355,966(-147.4%) | $751,571(-31.3%) | $1.1M(+543.9%) | $-246,469 |
| Total Assets | $9.3M | $10.4M | $11.4M | $8.7M | $9.6M | $10.1M | $1.2M |
| Total Debt | - | - | - | - | - | - | - |
| Total Equity | $8.6M | $8.3M | $9.7M | $6.7M | $7.2M | $6.7M | $1.1M |
| Profit Margin | -40.2% | -16.8% | -26.9% | -3.3% | 5.6% | 9.6% | -194.1% |
| ROE | -34.6% | -19.2% | -27.2% | -5.3% | 10.5% | 16.4% | -22.0% |
| ROA | -32.3% | -15.3% | -23.1% | -4.1% | 7.8% | 10.8% | -20.0% |
Quarterly Financials
Last 8 quarters| Metric | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.1M | $7.0M | $4.4M | $2.4M | $7.5M | $4.9M | $2.4M | $5.5M |
| Net Income | $-623,327 | $-1,250,023 | $95,347 | $-103,757 | $-69,066 | $-69,066 | $-69,066 | $17,066 |
| Total Assets | $9.3M | $10.4M | $10.4M | $10.4M | $11.4M | $11.4M | $11.4M | $8.7M |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026
Insider Trading
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
BioNexus Gene Lab Corp Free Cash Flow & Dividend Coverage
Cash Flow History
FY2019 - FY2025| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating CF | -$217,273 | $552,680 | $9,161 | $551,822 | -$1.8M | -$2.1M | -$1.8M |
| CapEx | -$12,817 | -$421,621 | -$3,162 | - | -$149,398 | -$226,989 | -$36,971 |
| Free Cash Flow | -$230,090 | $131,059 | $5,999 | $551,822 | -$2.0M | -$2.3M | -$1.9M |
| FCF Margin | -181.2% | 1.1% | 0.0% | 5.1% | -20.2% | -24.4% | -25.3% |
Source: SEC EDGAR 10-K filings. FCF = Operating Cash Flow - Capital Expenditures. Free cash flow guide
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026
BioNexus Gene Lab Corp Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
BioNexus Gene Lab Corp FAQ
Does BioNexus Gene Lab Corp pay dividends?
No, BioNexus Gene Lab Corp (BGLC) does not currently pay dividends to shareholders.
What is BioNexus Gene Lab Corp's financial health score?
BioNexus Gene Lab Corp has a financial health score of 29/100 (Grade: F), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of BioNexus Gene Lab Corp financial data are available?
7 years of financial data are available for BioNexus Gene Lab Corp from FY2019 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.